Stockreport

New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment

BioAge Labs, Inc.  (BIOA) 
Last bioage labs, inc. earnings: 8/3 07:00 am Check Earnings Report
US:NYSE Investor Relations: investor.bio-amber.com
PDF STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatme [Read more]